E0110000
Enalapril for system suitability
European Pharmacopoeia (EP) Reference Standard
동의어(들):
Enalapril maleate salt, (S)-N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-Ala-Pro maleate salt
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C20H28N2O5 · C4H4O4
CAS Number:
Molecular Weight:
492.52
UNSPSC 코드:
41116107
NACRES:
NA.24
추천 제품
Grade
pharmaceutical primary standard
API family
enalapril
제조업체/상표
EDQM
응용 분야
pharmaceutical (small molecule)
형식
neat
저장 온도
2-8°C
SMILES string
C[C@@H](C(N1[C@H](C(O)=O)CCC1)=O)N[C@H](CC(OCC)=O)CCC2=CC=CC=C2.O=C(OO)/C=C\C(O)=O
InChI
1S/C21H30N2O5.C4H4O5/c1-3-28-19(24)14-17(12-11-16-8-5-4-6-9-16)22-15(2)20(25)23-13-7-10-18(23)21(26)27;5-3(6)1-2-4(7)9-8/h4-6,8-9,15,17-18,22H,3,7,10-14H2,1-2H3,(H,26,27);1-2,8H,(H,5,6)/b;2-1-/t15-,17-,18-;/m0./s1
InChI key
UQKQUZOIQFOJOI-KJHLASMFSA-N
유사한 제품을 찾으십니까? 방문 제품 비교 안내
일반 설명
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
애플리케이션
Enalapril for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
생화학적/생리학적 작용
A long-acting angiotensin-converting enzyme inhibitor.
포장
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
기타 정보
Sales restrictions may apply.
관련 제품
제품 번호
설명
가격
신호어
Warning
유해 및 위험 성명서
예방조치 성명서
Hazard Classifications
Repr. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 2
가장 최신 버전 중 하나를 선택하세요:
Chrishan S Samuel et al.
Hypertension (Dallas, Tex. : 1979), 64(2), 315-322 (2014-05-29)
Relaxin is a naturally occurring peptide hormone that mediates systemic hemodynamic and renal adaptive changes during pregnancy and abrogates aberrant scar tissue formation (fibrosis) in diverse pathogeneses. However, its efficacy relative to renin–angiotensin system blockade, the most effective antifibrotic strategy
John J V McMurray et al.
The New England journal of medicine, 371(11), 993-1004 (2014-09-02)
We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. In this double-blind trial, we randomly assigned 8442 patients with class
Neprilysin inhibition--a novel therapy for heart failure.
Mariell Jessup
The New England journal of medicine, 371(11), 1062-1064 (2014-09-02)
[Heart failure and LCZ696].
Guy Sabourin
Perspective infirmiere : revue officielle de l'Ordre des infirmieres et infirmiers du Quebec, 12(1), 61-61 (2015-02-06)
Editorial comment.
Fernando Lorenzini
The Journal of urology, 192(6), 1883-1883 (2014-09-23)
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.